Christos Sotiriou

Christos Sotiriou

UNVERIFIED PROFILE

Are you Christos Sotiriou?   Register this Author

Register author
Christos Sotiriou

Christos Sotiriou

Publications by authors named "Christos Sotiriou"

Are you Christos Sotiriou?   Register this Author

100Publications

3777Reads

29Profile Views

Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.

Oncogene 2019 04 13;38(15):2814-2829. Epub 2018 Dec 13.

Pathology Unit, Department of Oncology, Microbiology and Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, 1700, Fribourg, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-018-0624-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477891PMC
April 2019

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays.

PLoS One 2018 31;13(8):e0203346. Epub 2018 Aug 31.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0203346PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118369PMC
February 2019

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2019 02;566(7742):E1

Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41586-019-0883-2
Publisher Site
http://dx.doi.org/10.1038/s41586-019-0883-2DOI Listing
February 2019

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Breast Cancer Res 2019 02 15;21(1):25. Epub 2019 Feb 15.

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1111-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377756PMC
February 2019

Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.

J Natl Cancer Inst 2019 Feb 21. Epub 2019 Feb 21.

Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, U-CRC, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz023DOI Listing
February 2019

pAKT pathway activation is associated with mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation.

NPJ Breast Cancer 2019 31;5. Epub 2019 Jan 31.

2Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0102-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355773PMC
January 2019

Network science in clinical trials: A patient-centered approach.

Semin Cancer Biol 2018 10 24;52(Pt 2):135-150. Epub 2017 Dec 24.

Bioinformatics and Computational Genomics Laboratory, Princess Margaret Cancer Center, Toronto, ON, Canada; Department of Computer Science, University of Toronto, Toronto, ON, Canada; Ontario Institute of Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2017.12.006DOI Listing
October 2018

Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.

J Natl Cancer Inst 2018 Oct;110(10):1115-1122

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro," Department of Clinical Sciences and Community Health, University of Milan, Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djy042DOI Listing
October 2018

Genomic hotspots but few recurrent fusion genes in breast cancer.

Genes Chromosomes Cancer 2018 07 22;57(7):331-338. Epub 2018 Mar 22.

IRIBHM, Université Libre de Bruxelles (ULB), 808 route de Lennik, Brussels, 1070, Belgium.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gcc.22533
Publisher Site
http://dx.doi.org/10.1002/gcc.22533DOI Listing
July 2018

Immunity drives regulation in cancer through NF-κB.

Sci Adv 2018 06 20;4(6):eaap7309. Epub 2018 Jun 20.

Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB (Université libre de Bruxelles)-Cancer Research Center (U-CRC), ULB, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/sciadv.aap7309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010319PMC
June 2018

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8301DOI Listing
April 2018

Recurrence dynamics of breast cancer according to baseline body mass index.

Eur J Cancer 2017 12 31;87:10-20. Epub 2017 Oct 31.

Unit of Medical Statistics, Biometry and Bioinformatics "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health, University of Milan Campus Cascina Rosa, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.10.007DOI Listing
December 2017

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Nov;24(6):311-335

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638696PMC
November 2017

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Cancer Res 2017 10 30;77(20):5652-5663. Epub 2017 Aug 30.

Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-0707DOI Listing
October 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Sep;24(5):235-251

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564448PMC
September 2017

DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

J Clin Invest 2017 Aug 17;127(8):3090-3102. Epub 2017 Jul 17.

Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI91095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531413PMC
August 2017

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data.

Clin Cancer Res 2017 Jun 9;23(11):2702-2712. Epub 2016 Nov 9.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brusells, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0979DOI Listing
June 2017

Transcriptomic and genomic features of invasive lobular breast cancer.

Semin Cancer Biol 2017 06 8;44:98-105. Epub 2017 Apr 8.

Breast Cancer Translational Research Laboratory J.-C. Heuson, Université Libre de Bruxelles, Institut Jules Bordet, 1000 Brussels, Belgium; Department of Pathology/TCRU, Sint Augustinus, Wilrijk, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2017.03.007DOI Listing
June 2017

MetaDCN: meta-analysis framework for differential co-expression network detection with an application in breast cancer.

Bioinformatics 2017 Apr;33(8):1121-1129

Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/btw788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041767PMC
April 2017

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

J Natl Cancer Inst 2017 01 13;109(1). Epub 2016 Oct 13.

Affiliations of authors: Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (RDB, MATMvV, EGEdV, CPS, RSNF); Department of Medical Oncology and Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium (CS, MJPG); Division of Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands (JBAGH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284248PMC
January 2017

Portraying breast cancers with long noncoding RNAs.

Sci Adv 2016 09 2;2(9):e1600220. Epub 2016 Sep 2.

Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB-Cancer Research Center (U-CRC), Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/sciadv.1600220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010371PMC
September 2016

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

N Engl J Med 2016 Aug;375(8):717-29

From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (L.J.V.); European Organization for Research and Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - all in France; Swiss Institute of Bioinformatics and University of Lausanne, Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1602253DOI Listing
August 2016

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

J Clin Oncol 2016 06 29;34(16):1872-81. Epub 2016 Feb 29.

Christine Desmedt, Gabriele Zoppoli, Denis Larsimont, Debora Fumagalli, David Brown, Françoise Rothé, Delphine Vincent, Naima Kheddoumi, Ghizlane Rouas, Samira Majjaj, Sylvain Brohée, Roberto Salgado, Martine Piccart-Gebhart, and Christos Sotiriou, Institut Jules Bordet; Christine Galant, Cliniques Universitaires Saint Luc, Brussels; Peter Van Loo, University of Leuven; Thomas Van Brussel and Diether Lambrechts, VIB Vesalius Research Center, Leuven, Belgium; Gabriele Zoppoli, University of Genoa and Istituto di Ricerca a Carattere Clinico-Scientifico San Martino-National Cancer Institute, Genoa; Giancarlo Pruneri, Patrick Maisonneuve, and Giuseppe Viale, European Institute of Oncology; Marco Fornili and Elia Biganzoli, University of Milan, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy; Gunes Gundem and Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridgeshire; Peter Van Loo, The Francis Crick Institute, London, United Kingdom; Ron Bose, Washington University School of Medicine, St Louis, MO; Otto Metzger, Dana-Farber Cancer Institute, Boston, MA; and François Bertucci, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0334DOI Listing
June 2016

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2016 06 2;534(7605):47-54. Epub 2016 May 2.

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature17676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910866PMC
June 2016

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Nat Rev Clin Oncol 2016 Apr 15;13(4):228-41. Epub 2015 Dec 15.

Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, East Melbourne, Victoria 8006, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.215DOI Listing
April 2016

MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.

Mol Biosyst 2016 Feb;12(2):404-13

Laboratory of Cancer Epigenetics, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c5mb00513bDOI Listing
February 2016

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

JAMA Oncol 2016 Feb;2(2):217-24

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium2Medical Oncology Clinic, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4377DOI Listing
February 2016

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Cancer Res 2016 Jan 7;76(2):264-74. Epub 2016 Jan 7.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. School of Medicine, University of Queensland, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1567DOI Listing
January 2016

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now?

Clin Cancer Res 2015 Nov;21(21):4743-6

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium. Department of Medical Oncology, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-3127DOI Listing
November 2015

Genomic aberrations in young and elderly  breast cancer patients.

BMC Med 2015 Oct 15;13:266. Epub 2015 Oct 15.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo, 121, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12916-015-0504-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606505PMC
October 2015

New approaches for improving outcomes in breast cancer in Europe.

Breast 2015 Aug 31;24(4):321-30. Epub 2015 Mar 31.

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.03.001DOI Listing
August 2015

Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.

Clin Adv Hematol Oncol 2015 Jun;13(6):372-82

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
June 2015

Evolving paradigms in multifocal breast cancer.

Semin Cancer Biol 2015 Apr 24;31:111-8. Epub 2014 Jul 24.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2014.07.002DOI Listing
April 2015

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

J Clin Oncol 2015 Apr 5;33(12):1334-9. Epub 2015 Jan 5.

Ian J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087318PMC
April 2015

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

J Clin Oncol 2015 Mar 22;33(9):983-91. Epub 2014 Dec 22.

Carsten Denkert, Bruno V. Sinn, Berit M. Pfitzner, Wolfgang D. Schmitt, Silvia Darb-Esfahan, Stephan Wienert, Frederick Klauschen, and Manfred Dietel, Charité Universitätsmedizin Berlin; Carsten Denkert, German Cancer Consortium (DKTK); Peter Klare, Praxisklinik and Breast Center; Jens-Uwe Blohmer, St Gertrauden Krankenhaus and Charité Universitätsmedizin; Micheal Untch, Helios Klinikum Berlin-Buch, Berlin; Gunter von Minckwitz, Stephan Gade, Keyur Mehta, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Women's Hospital, University of Frankfurt; Hans Tesch, Bethanien Hospital, Frankfurt; Jan C. Brase, Ralf Kronenwett, Karin Fisch, and Kristin Krappmann, Sividon Diagnostics, Cologne; Ralf Kronenwett, Heinrich-Heine University Düsseldorf, Düsseldorf; Christian Schem, Christian-Albrechts Universität zu Kiel, Kiel; Christoph Salat, Onkologische Schwerpunktpraxis, Munich; Marcus Schmidt, Johannes-Gutenberg Universität Mainz, Mainz; Sherko Kümmel, Kliniken Essen-Mitte, Essen; Peter Sinn, University of Heidelberg, Heidelberg; Christian Jakisch and Sibylle Loibl, Sana Klinikum Offenbach, Offenbach; Toralf Reimer, Klinikum Südstadt, Rostock, Germany; Sherene Loi, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; Sherene Loi and Christos Sotiriou, Institute Jules Bordet, Brussels, Belgium; and Fabrice André, Institute Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1967DOI Listing
March 2015

No significant viral transcription detected in whole breast cancer transcriptomes.

BMC Cancer 2015 Mar 18;15:147. Epub 2015 Mar 18.

IRIBHM - Université Libre de Bruxelles, ULB, Campus Erasme CP602, 808 route de Lennik, 1070, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1176-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374178PMC
March 2015

New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors.

Clin Cancer Res 2014 Dec 21;20(24):6242-6. Epub 2014 Oct 21.

BrEAST Data Center, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-1086DOI Listing
December 2014

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Cancer Treat Rev 2014 Oct 12;40(9):1089-95. Epub 2014 Aug 12.

BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.07.005DOI Listing
October 2014

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

J Clin Oncol 2014 Oct 8;32(29):3212-20. Epub 2014 Sep 8.

Sibylle Loibl, Sana Klinikum, Offenbach; Sibylle Loibl, Gunter von Minckwitz, Sanxing Guo, Stephan Gade, and Valentina Nekljudov, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Universitäts-Frauenklinik; Fariba Khandan, Agaplesion Markus Krankenhaus; Clemens Heinrichs, OptiPath, Frankfurt; Andreas Schneeweiss and Peter Sinn, Nationales Centrum für Tumorerkrankungen, Heidelberg; Stephan Paepke, Klinikum Rechts der Isar der Technischen Universität, München; Annika Lehmann, Berit Pfitzner, Judith L. Lindner, and Carsten Denkert, Charité Universitätsmedizin; Michael Untch, Helios-Klinikum, Berlin; Mahdi Rezai, Luisenkrankenhaus; Karel Dohnal, Centre for Pathology and Cytology, Düsseldorf; Dirk M. Zahm, SRH Waldklinikum, Gera; Holger Eidtmann, Universitäts-Frauenklinik, Kiel; Jens Huober, Universitäts-Frauenklinik, Ulm; Peter A. Fasching, Universitäts-Frauenklinik, Erlangen; August Dykgers, St Josef Hospital, Dortmund, Germany; Fabrice Andre, Institute Gustave Roussy, Villeueve, France; Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium; and Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7876DOI Listing
October 2014

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

J Clin Oncol 2014 Sep 21;32(25):2794-803. Epub 2014 Jul 21.

Felipe Ades, Lina Pugliano, Debora Fumagalli, Evandro de Azambuja, Christos Sotiriou, and Martine Piccart, Institut Jules Bordet, Université Libre de Bruxelles; Dimitrios Zardavas, Breast International Group, Brussels, Belgium; Ivana Bozovic-Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; and Giuseppe Viale, European Institute of Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1870DOI Listing
September 2014

Biology of breast cancer during pregnancy using genomic profiling.

Endocr Relat Cancer 2014 Aug 13;21(4):545-54. Epub 2014 May 13.

Department of MedicineInstitut Jules Bordet, BrEAST Data Centre, Université Libre de Bruxelles (ULB), Boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory (BCTL) J. C. HeusonInstitut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BelgiumDepartment of MedicineInstitut Jules Bordet, BrEAST Data Centre, Université Libre de Bruxelles (ULB), Boulevard de Waterloo, 121, 1000 Brussels, BelgiumBreast Cancer Translational Research Laboratory (BCTL) J. C. HeusonInstitut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, BelgiumFertility and Procreation UnitDepartment of Gynecologic Oncology, European Institute of Oncology, Milan, ItalyTranslational Breast Cancer Genomic LabCancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, AustraliaSir Peter MacCallum Department of OncologyUniversity of Melbourne, Parkville, Victoria, AustraliaVesalius Research CentreVIB, Leuven, BelgiumLaboratory of Translational GeneticsDepartment of Oncology, University of Leuven, Leuven, BelgiumDepartment of PathologyDivision of Epidemiology and BiostatisticsEuropean Institute of Oncology, Milan, ItalyDepartment of MedicineMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxel

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-14-0111DOI Listing
August 2014

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

Science 2014 Aug;345(6196):1251343

Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.1251343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380235PMC
August 2014

Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment.

Analyst 2014 Mar;139(5):1044-56

Laboratory for the Structure and Function of Biological Membranes, Center for Structural Biology and Bioinformatics, Université Libre de Bruxelles (ULB), Bld du Triomphe 2, CP206/2, B1050 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c3an01454aDOI Listing
March 2014

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.

Breast 2013 Dec 20;22(6):1060-5. Epub 2013 Sep 20.

Breast Cancer Translational Research Laboratory, J.C. Heuson, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.014DOI Listing
December 2013

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Future Oncol 2013 Oct;9(10):1477-87

'Sandro Pitigliani' Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.13.103DOI Listing
October 2013

Luminal breast cancer: from biology to treatment.

Nat Rev Clin Oncol 2013 Sep 23;10(9):494-506. Epub 2013 Jul 23.

Department of Medical Oncology and Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.124DOI Listing
September 2013

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.

J Natl Cancer Inst 2013 Jul 5;105(13):960-7. Epub 2013 Jun 5.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699437PMC
July 2013